On October 9, 2018 Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax’s intratumoral TLR9 agonist, in combination with KEYTRUDA (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada) (Press release, Dynavax Technologies, OCT 9, 2018, View Source [SID1234530122]). Data will be presented in three individual sessions with data for advanced melanoma patients who are naïve to anti-PD-1 therapy being presented as a late-breaking abstract poster discussion, at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2018 Congress, being held October 19-23, 2018 in Munich Germany.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The details of the poster presentations and discussion sessions are as follows:
Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Poster Discussion Session: Head and Neck Cancers
Final Publication Number: 1050PD
Discussion Session Date/Time: Saturday, October 20, 2018, 3:00 PM – 4:15 PM CEST
Discussion Session Location: Hall B3 – Room 23, ICM München, Munich Germany
Poster Session Date/Time: Saturday, October 20, 9:00 AM CEST to Monday, October 22, 5:00 PM CEST
Poster Session Location: Hall B4 – ICM München, Munich Germany
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy
Poster Discussion Session: Melanoma and Other Skin Tumours
Final Publication Number: LBA45
Discussion Session Date/Time: Saturday, October 20, 2018, 2:45 PM – 4:05 PM CEST
Discussion Session Location: ICM – Room 14b, ICM München, Munich Germany
Poster Session Date/Time: Saturday, October 20, 2:45 PM CEST to Monday, October 22, 5:00 PM CEST
Poster Session Location: Hall B4 – ICM München, Munich Germany
Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy
Poster Session: Basic science, Endocrine tumours, Gastrointestinal tumours – colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Final Publication Number: 1265P
Poster Session Date/Time: Sunday, October 21, 12:45 PM – 1:45 PM CEST
Poster Session Location: Hall A3 – Poster Area Networking Hub, ICM München, Munich Germany